TETRAFERRIC TRICITRATE DECAHYDRATE

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	3C6H4O7.4Fe.10H2O
Molecular Weight	967.808
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of TETRAFERRIC TRICITRATE DECAHYDRATE

Structure Search

SMILES

O.O.O.O.O.O.O.O.O.O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O

InChI

InChIKey=UISKQNNAQKPSDO-UHFFFAOYSA-E

InChI=1S/3C6H7O7.4Fe.10H2O/c3*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;;;;;;;;;;/h3*1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;;10*1H2/q3*-1;4*+3;;;;;;;;;;/p-9

HIDE SMILES / InChI

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C6H8O7
Molecular Weight	192.1235
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Fe
Molecular Weight	55.845
Charge	3
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.mfc.co.jp/english/eng/product/sanferol/pdf/fls_gras_notice.pdfhttps://mistralhowto.wordpress.com/2012/03/12/what-is-pigment-yellow-42-and-what-is-it-used-for/ | http://sensientfoodcolors.com/en-us/confection/iron-oxides-approved-by-the-fda/ | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=73.2250 | https://www.drugs.com/inactive/ferric-oxide-yellow-381.htmlhttps://books.google.ru/books?id=vxtxWneRBN4C&pg=PA1103&#v=onepage&q&f=falsehttps://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205874Orig1s000PharmR.pdfhttp://www.edta-chelate.com/ferric-ammonium-edta-liquid--1640836.htmlhttps://books.google.ru/books?id=3hLmyma2-MsC&pg=PA241&lpg=PA241&dq=FERRIC+AMMONIUM+CHLORIDE retrieved from A Consumer's Dictionary of Cosmetic Ingredients, 7th Edition: Complete Information About the Harmful and Desirable Ingredients Found in Cosmetics and Cosmeceuticals By Ruth Winterhttps://www.ncbi.nlm.nih.gov/pubmed/27995746 | http://onlinelibrary.wiley.com/doi/10.1002/047084289X.rn01568/abstract?userIsAuthenticated=false&deniedAccessCustomisedMessage=https://cameochemicals.noaa.gov/chemical/3468 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.ncbi.nlm.nih.gov/pubmed/27684194 | https://www.ncbi.nlm.nih.gov/pubmed/17511797 | https://www.ncbi.nlm.nih.gov/pubmed/1427505
Curator's Comment: description was created based on several sources, including https://www.gpo.gov/fdsys/pkg/CFR-1996-title21-vol3/pdf/CFR-1996-title21-vol3-sec182-5375.pdf

Ferric chloride is a compound used as a food additive, a haemostatic or treatment for hypochromic anaemia. Ferric chloride induced vascular injury is a widely used model of occlusive thrombosis that reports platelet activation and aggregation in the context of an aseptic closed vascular system. Iron i.v. ferric chloride (960 mg) has being shown to be effective in correcting anaemia in HD patients with iron deficiency.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
transformed cell apoptotic process 108 Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21121365	Activator 1430
Phosphate 44 Target ID: CHEMBL2364184 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205874Orig1s000PharmR.pdf	Chelating Agent 142

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
Unknown 2578
Parenteral Nutrition 50 Sources: https://www.hpra.ie/img/uploaded/swedocuments/2124555.PA0566_015_002.9e9eecde-fb07-4612-8f14-39d5233b7ace.000001Product%20Leaflet%20Approved.150327.pdf https://www.ncbi.nlm.nih.gov/pubmed/20377770	Primary	Approved 8429	Additrace N Approved Use A source of electrolytes and trace elements as an integral part of a complete intravenous nutritional regimen, for adults and children over 40 kg.
Iron deficiency 80 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17511797	Preventing	Approved 8429	Parmirin Approved Use Preventive treatment of iron deficiency
Dental diseases 45 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13224146 https://www.ncbi.nlm.nih.gov/pubmed/286710	Primary	Basic research	Unknown Approved Use Unknown
Iron deficiency anemia 56 Sources: http://www.mfc.co.jp/english/eng/product/sanferol/page/3_11.html	Primary	Approved 8429	SANFEROL Approved Use It has also been reported that SFC preparation improved iron deficiency in a pregnant woman with iron deficiency anemia whose hemoglobin level had not increased after administration of other iron preparations such as ferrous fumarate. A dairy supplemental dose of SFC improved iron deficiency in young women with iron deficiency.
Unknown 2578
Pain 614 Sources: https://www.drugs.com/inactive/ferric-oxide-yellow-381.html https://www.drugs.com/imprints/op-40-16159.html	Inactive ingredient	Approved 8429	Oxycontin Approved Use OxyContin is used in the treatment of chronic pain; pain and belongs to the drug class narcotic analgesics. Launch Date 9.0935997E11
Unknown 2578
Radioactive cesium and/or radioactive or non-radioactive thallium internal contamination 44 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021626lbl.pdf	Curative	Approved 8429	RADIOGARDASE Approved Use Insoluble Prussian blue is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination. Launch Date 1.06496642E12
Chronic kidney disease 56 Sources: https://www.drugs.com/pro/ferric-citrate-tablets.html	Palliative	Approved 8429	AURYXIA Approved Use Ferric Citrate is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. Launch Date 1.40978881E12

PubMed

Title	Date	PubMed
Biological availability of iron supplements for rats, chicks and humans.	1976 Feb	1249649
Contact dermatitis to yellow iron oxide.	1985 Aug	4064645
Carcinogenicity studies on natural and man-made fibres with the intraperitoneal test in rats.	1989	2744824
Metal-mediated cyclization of aryl and benzyl glycidyl ethers: a complete scenario.	2008 Dec 17	19053452
Thermal behavior study and decomposition kinetics of amiodarone hydrochloride under isothermal conditions.	2011 Jun	21449701
Finnish wallpaper pigments in the 18th-19th century: presence of KFe3(CrO4)2(OH)6 and odd pigment mixtures.	2013 Apr	23376265
Mechanisms and origins of the switchable regioselectivity of FeBr3-catalyzed [1,2]-aryl and [1,2]-alkyl shifts of α-aryl aldehydes.	2016 Feb 28	26822257
Halide Influence on Molecular and Supramolecular Arrangements of Iron Complexes with a 3,5-Bis(2-Pyridyl)-1,2,4,6-Thiatriazine Ligand.	2016 Jun 6	27152549
Iron-Catalyzed Regioselective Transfer Hydrogenative Couplings of Unactivated Aldehydes with Simple Alkenes.	2016 May 17	27072872

Patents

Sample Use Guides

In Vivo Use Guide

Ferric sodium citrate is an additive used in various foods such as baby milk powder, school and hospital food, beverages, cereals and supplements. It is administered orally.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 16 08:27:09 UTC 2023` Edited by `admin` on `Sat Dec 16 08:27:09 UTC 2023`
Record UNII	Q91187K011
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TETRAFERRIC TRICITRATE DECAHYDRATE

Common Name

English

AURYXIA

Brand Name

English

KRX-0502

Code

English

IRON (AS FERRIC CITRATE) [VANDF]

Common Name

English

1,2,3-PROPANETRICARBOXYLIC ACID, 2-HYDROXY-, IRON(3+) SALT, HYDRATE (4:3:10)

Systematic Name

English

FERRIC CITRATE [USAN]

Common Name

English

Code System Code Type Description

FDA UNII

Q91187K011